Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market
|出版商||Frost & Sullivan||商品編碼||1008338|
|出版日期||內容資訊||英文 67 Pages
|CRO（合同研究組織）的全球市場：自新型冠狀病毒感染（COVID-19）以來的趨勢造成的混亂 Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market|
|出版日期: 2021年05月13日||內容資訊: 英文 67 Pages||
全球CRO市場多年來一直停滯不前，但由於新型冠狀病毒感染（COVID-19）疫苗的快速研發（R&D），2020年有顯著增長。去中心化臨床試驗（DCT）開始投入實際應用，併購（M&A）和新進入者變得更加活躍。即使是小規模的 CRO 也越來越多地致力於通過開發罕見疾病的治療藥物和慢性病的生物仿製藥，以及促進功能服務提供商 (FSP) 模式的引入來發展他們的業務並確保和擴大合作夥伴。對以患者為中心和臨床試驗多樣性日益增長的興趣正在為 CRO 和技術供應商創造新的增長機會。
本報告分析了全球 CRO（合同研究機構）行業的前景和挑戰，以及 COVID-19 之後的市場前景和成熟度，整體市場規模趨勢前景，按細分市場。詳細趨勢（臨床/非臨床等）)、主要的市場推動/制約因素、競爭環境、近期的重大動向（併購/資本交易等）、未來的增長機會和當前的緊迫問題等。
Increased Focus on Patient Centricity and Diversity in Clinical Trials Provide Growth Opportunities for CROs and Technology Vendors
Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the market's maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs, and estimates growth patterns for the next five years based on detailed analyses of drug and biologics interventional trials, outsourcing penetration rates, and cost variations. It further provides insights into the driving influences and challenges across regions and clinical development phases.
The plateaued CRO market experienced a sudden growth in 2020 due to the surge in research and development (R&D) efforts related to COVID-19 therapies and vaccines. The CRO market, fragmented with more than 1,000 participants, has two broad segments: nonclinical, which includes drug discovery and preclinical services, and clinical. Recent big acquisitions in the market may indicate a trend of future mergers or partnerships with integrated e-clinical platform providers as global CROs focus on building capabilities in innovative patient-centric clinical trial delivery models. Decentralized clinical trials (DCTs), while still at a nascent stage, are enabling newer participants to enter the clinical trial industry. Recent initiatives by the Decentralized Trials & Research Alliance to bring together industry participants, including CROs, pharma/biotech sponsors, and technology vendors, have increased awareness of DCTs globally and catapulted their adoption especially in North America. To adapt to DCTs, sponsors will increasingly rely on CROs to expedite the implementation of telemedicine components and remote monitoring solutions in clinical research due to inconsistencies in laws and regulations across the globe.
The rising need to maximize R&D productivity and global penetration has led to an increase in multicountry trial registrations by pharma/biotech sponsors. Several small biotech companies that support the development of therapies for rare/orphan diseases and biosimilars for chronic diseases are contributing to the CRO market growth. The continuous expansion in personalized medicine and cell and gene therapies, potency and biomarker assay complexities, and the need for adaptive trial designs is increasing outsourcing penetration to CROs. However, the shortage of skilled workforce with knowledge of the dynamic regulatory requirements to support complex therapies development can hinder the CRO market growth.
Patient-centric solutions and data-driven portfolios are fueling the adoption of functional service provider (FSP) models, even among small and midsize pharma companies. FSP partnerships enable them to rapidly scale their workforce to match business demand and distribute risk across programs or portfolios. Asia-Pacific customers are increasingly using outsourcing and insourcing FSP models in their partnerships to enhance traditional working models, resulting in greater value sharing, support, and access to expertise. Lastly, the need to develop highly efficacious therapies through innovation has boosted the growth of drug-device combination therapies, leading to more partnerships between medtech participants, CROs, and pharma companies for clinical development programs.